TRT and breast cancer: what survivors need to know

What did @mychinadolls143 actually say?

She's a breast cancer survivor, ER-positive/PR-positive/HER2-negative, and she's explaining her post-treatment regimen. She takes what she calls "an esterazol" (anastrozole) daily for 10 years, gets monthly Zoladex (goserelin) injections to keep her in a medically induced menopause, and will receive zoledronic acid (Zometa) infusions to protect her bones. She describes anastrozole as "an AI inhibitor" that "stops estrogen from forming" in her body, contrasts it with tamoxifen, and explains the joint and bone pain side effects plainly and without exaggeration.

This is a patient talking about her own treatment, not prescribing to anyone. That context matters. She's sharing lived experience, and most of what she says tracks with the clinical record reasonably well.

Does the science back this up?

Yes, mostly. Aromatase inhibitors like anastrozole are the standard adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer, and the 10-year duration she mentions is now supported by evidence. The bone pain is real and documented.

The ATAC trial (Howell et al., 2005, The Lancet) established anastrozole's superiority over tamoxifen in postmenopausal HR-positive breast cancer, and extended follow-up confirmed sustained disease-free survival benefits. The MA.17R trial (Goss et al., 2016, New England Journal of Medicine) demonstrated that extending aromatase inhibitor therapy beyond five years, out to ten years, further reduced recurrence risk. So the ten-year number she cites is not arbitrary. It reflects a real shift in clinical guidelines for higher-risk patients.

Her bone concern is also well-founded. Aromatase inhibitors suppress estrogen more completely than tamoxifen and accelerate bone mineral density loss. Zoledronic acid infusions in this context have evidence behind them. The AZURE trial (Coleman et al., 2011, New England Journal of Medicine) showed zoledronic acid reduced bone metastasis risk in premenopausal patients receiving ovarian suppression, which is exactly her situation.

What did they get wrong (or right)?

The terminology is imprecise but not dangerous. She calls anastrozole "an AI inhibitor" when the correct term is aromatase inhibitor, or AI. Minor. She also says it "stops estrogen from forming," which is a simplification. Anastrozole inhibits the aromatase enzyme that converts androgens into estrogen in peripheral tissues. It doesn't stop all estrogen production everywhere, but in a postmenopausal context with ovarian suppression added, the effect is close enough to what she described for a lay explanation.

She conflates two different mechanisms when comparing anastrozole and tamoxifen. Tamoxifen is a selective estrogen receptor modulator, not an aromatase inhibitor. They both reduce estrogen's effect on tumors but through completely different pathways. She frames it as the same category of drug, which it isn't. That said, she doesn't make any dangerous claims from this imprecision.

Calling Zoladex "zillaDex" is just a pronunciation issue. The drug is goserelin, a GnRH agonist used to suppress ovarian function in premenopausal women with HR-positive breast cancer. Her description of why she takes it, to stay in menopause so the anastrozole works, is clinically correct. Aromatase inhibitors require a postmenopausal estrogen environment to be effective, and Zoladex creates that artificially.

What should you actually know?

If you're in a similar position, or someone you know is, the regimen she's describing is not fringe. It's guideline-concordant care for premenopausal women with higher-risk, HR-positive breast cancer. The SOFT and TEXT trials (Francis et al., 2015, New England Journal of Medicine) showed that combining ovarian suppression with an aromatase inhibitor outperformed tamoxifen alone in women under 35 or with higher recurrence risk. Her oncologist appears to have followed that evidence.

The bone pain she describes, feeling "like I'm 100 years old," is a well-documented side effect called aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). Estimates suggest 30-50% of patients experience it, and it's one of the main reasons people stop treatment early. That's a real problem because stopping early increases recurrence risk.

• Anastrozole and tamoxifen are both used in HR-positive breast cancer but work differently. They are not interchangeable categories.
• The 10-year duration she mentions is evidence-based for higher-risk patients, not arbitrary.
• Zoladex (goserelin) is a legitimate adjunct to make aromatase inhibitors work in premenopausal women.
• Zometa (zoledronic acid) for bone protection in this setting has clinical trial support.
• Joint and bone pain from anastrozole is common enough to be a named syndrome. If it's affecting your adherence, talk to your oncologist. Options exist.